The main purpose of the trial is to determine whether the experimental cell therapy can improve lung function compared with standard care. Participants are randomly assigned to receive either the new cell therapy or the usual medicines, and the study is open‑label, meaning both doctors and participants know which treatment is being given. After the initial treatment, participants attend regular clinic visits for several months during which safety checks and health assessments are performed.

Effectiveness is primarily measured by changes in Forced Vital Capacity, which is the amount of air a person can forcefully exhale after a deep breath. Secondary evaluations include the Modified Rodnan Skin Score, a simple scale that rates skin thickness, and the DLCO, a test that shows how well the lungs transfer oxygen into the blood. Additional observations track how lung function and skin thickness change over time and how long it takes for the disease to worsen.

Participants will receive one of the two treatments for a defined period and will undergo two imaging procedures: a scan called 18F-FDG PET/CT, which shows how the heart uses sugar, and a scan named 99mTc-Tetrofosmin SPECT, which visualizes blood flow in the heart. These scans are performed at the beginning of the study and after the treatment phase to compare changes. Throughout the study, participants will attend regular visits for safety checks and to collect information about heart function and blood flow.

The study is testing whether an experimental medicine named prasinezumab can help protect thinking skills in these individuals. The drug is given through an IV infusion, which means it is delivered directly into the bloodstream using a small tube inserted into a vein. Participants will receive either the medicine or a placebo, a simple salt solution that looks the same as the active treatment, so that neither the participants nor the doctors know which one is given. The main goal is to see if the medicine can slow or prevent loss of mental function compared with the placebo.

People who join the trial will come to the clinic for regular visits over about two years. At each visit they will have brief safety checks such as blood tests and heart monitoring, and they will complete simple questionnaires and short memory and thinking tests that are easy to understand. The schedule includes several infusion sessions spaced out over the study period, allowing researchers to track any changes in thinking abilities and overall health throughout the trial.

The purpose is to determine whether long‑term use of Admilparant is safe and does not lead to serious side effects.

Participants will take one tablet each day for several years while doctors perform regular check‑ups. At each visit routine blood work, a quick heart test called an ECG that records the heart’s electrical activity, and measurements of blood pressure and heart rate are done. The study records any side effects, changes in test results, or reasons to stop the medication, and follows each person from the start until the study ends.

The purpose of the study is to determine whether nemolizumab can safely reduce skin thickness and improve overall health in adults with Systemic sclerosis while identifying the most effective dose.

Adults who join the trial will receive a series of subcutaneous injections over a 52‑week main treatment period, after which they may continue receiving the medication for an additional 156 weeks if they choose to stay in the study. Throughout the study, participants will have regular clinic visits where doctors will assess skin thickness using a scoring system called the modified Rodnan Skin Score, measure lung capacity with a test known as forced vital capacity, and evaluate overall response using the Composite Response Index in Systemic Sclerosis. Safety will be monitored by checking vital signs, laboratory tests, and any side effects that arise.

The purpose of the trial is to evaluate the long‑term safety and tolerability of the study drug in this patient population. After an initial screening, participants will receive the assigned medication at regular intervals over an extended period while undergoing routine health checks, including measurements of vital signs, blood laboratory tests, and a heart test known as an electrocardiogram. Physical examinations will assess walking ability, standing up from the floor, climbing stairs, and upper‑limb function, and blood samples will be taken to monitor drug levels and any immune response. The study is open‑label, so all participants know they are receiving the investigational therapy, and it continues beyond the earlier phase of the research.

The purpose of the study is to assess the safety and tolerability of the different treatment regimens. After an initial screening visit, participants will begin a series of injection visits that continue for several months, with regular clinic appointments to check health status, record any side effects, and perform routine laboratory tests. The study follows participants for up to about four years to observe long‑term outcomes.

Safety monitoring includes tracking any new medical problems that arise during the trial. In addition, doctors will use a camera procedure called endoscopic examination to look inside the colon and evaluate improvement of the disease after about one year. This information, together with the safety data, helps determine whether the antibodies are well tolerated and potentially beneficial for people with ulcerative colitis.

The purpose of the trial is to determine whether the combination of these therapies can keep the cancer from returning for a longer time compared with placebo.

After surgery, participants are randomly assigned to receive either the active combination of medicines or the placebo, with injections given at regular intervals over several months. Throughout the study, participants attend follow‑up visits where doctors check for any side effects, monitor overall health, and perform routine scans or tests to see if the cancer comes back.

Participants receive the medication by an intravenous infusion, meaning it is given through a vein, with the amount of drug increased gradually in the early part of the study to find a safe level, followed by a larger group receiving that level to see early signs of effectiveness. Throughout the study, regular blood tests are done to measure PSA (a protein that can indicate prostate cancer activity), check organ function, and look for any side effects. Imaging scans are also performed at set intervals to see if tumors shrink or stop growing. The study follows each participant for several months, recording any adverse events, changes in laboratory results, and overall health status.

The primary aim of the trial is to determine whether the new combination improves the time patients live without their disease getting worse and, for a portion of the study, also extends overall survival compared with standard care.

Participants are randomly assigned to receive either the experimental medicines or the usual therapy, with treatment given in repeated cycles of intravenous infusions and oral tablets over several months. Throughout the study, doctors monitor tumor size using imaging scans evaluated by the criteria called RECIST 1.1, record how long the disease stays stable (progression free survival), note the length of life from start of treatment (overall survival), and assess how many patients experience tumor shrinkage (objective response rate). Safety is evaluated by tracking side effects, vital signs, laboratory tests and heart rhythm recordings.

The purpose of the study is to demonstrate that tirzepatide is superior to placebo for glycemic control; participants are randomly assigned to receive either tirzepatide or a placebo, and neither the participants nor the study staff know which treatment is being given.

The study lasts about 40 weeks, during which the assigned injection is taken each week and regular clinic visits are made to check blood sugar, weight, and safety. Blood sugar control is measured with a test called Hemoglobin A1c (HbA1c), which shows the average level of glucose in the blood over the past two to three months. Obesity and overweight describe a condition where body weight is higher than what is considered healthy for a person’s height.

This clinical trial is focused on studying Type 1 Diabetes in adults who are also overweight or have obesity. The treatment being tested is called tirzepatide (also known by its code name LY3298176), which is given as a solution for injection using a pre-filled pen. The purpose of the study is to see if tirzepatide can help control blood sugar levels better than a placebo.

Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 40 weeks. During this time, the effects of tirzepatide on blood sugar levels will be closely monitored. The study aims to determine if tirzepatide is more effective than a placebo in managing blood sugar levels in people with Type 1 Diabetes.

This study is important for understanding how tirzepatide can help people with Type 1 Diabetes who are also dealing with being overweight or obese. The results could provide valuable insights into new treatment options for better managing blood sugar levels in these individuals.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

Participants in the study will receive Nemtabrutinib in the form of a tablet taken by mouth. The study is divided into two parts. In the first part, the focus is on understanding the safety and how well the body can tolerate Nemtabrutinib. In the second part, the study will look at how well the medication works in treating the different types of blood cancers mentioned. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Nemtabrutinib.

The study will take place over a period of time, with participants being monitored for any side effects and the effectiveness of the treatment. The goal is to gather information that could help improve treatment options for people with these types of blood cancers. Participants will be closely observed by medical professionals throughout the study to ensure their safety and to collect valuable data on the medication’s impact.

Participants will receive the medicine according to the doctor’s plan and will be followed for several months. During the follow‑up they will have routine lab tests that check things such as the amount of protein in the urine, kidney function measured by eGFR, and blood levels of waste products. Doctors will also record any serious side effects, hospital visits, or need for treatments like dialysis, kidney transplant, or management of nephrotic syndrome. Information will be collected at regular intervals, such as every few months, to see how the disease and the patient’s health change over time.

The purpose of the trial is to find out whether adding the study drug to the steroid‑taper plan can achieve better sustained remission after one year compared with the steroid taper alone. The study is designed to be randomized (participants are assigned to groups by chance) and double‑blind (neither the participants nor the doctors know which injection is being given). Over about a year, participants will attend regular visits where their symptoms, blood tests, and questionnaires about physical and mental health are checked, and any side effects will be recorded.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

People with the condition will take the test powder by mouth and then provide urine samples a few hours later, while blood and stool samples will also be collected at scheduled visits. These visits will occur at the start of the study, after about six months, and again after twelve months, during which the usual diet advice will continue. The study will compare the test results with standard assessments such as the Marsh-Oberhuber classification that describes the degree of intestinal damage, to determine whether the test reliably reflects changes in the gut over time.

The purpose of the study is to find out whether the chloramphenicol drops work at least as well as the ciprofloxacin drops in stopping ear discharge in adults with this condition. Participants will use the assigned ear drops for about two weeks. Doctors will examine the ear using a light‑based tool (otoscopy) and take pictures to see if the discharge has cleared. Hearing will be checked with a simple beep test (pure‑tone audiometry) at the start and after the treatment period. Throughout the study, participants will note any irritation, pain, or other side effects and answer questions about how they feel and how satisfied they are with the treatment.

Participants are assigned at random to receive either ASP3082 plus chemotherapy or the placebo plus chemotherapy. The study drug is delivered by intravenous infusion, a process where the medication is slowly introduced into a vein. Treatment cycles are repeated every few weeks, and patients are monitored over several months for changes in tumor size, side effects, and overall health status before the study concludes.

The purpose of the study is to evaluate the safety and tolerability of this therapy in the early weeks after it is given. Participants will undergo a screening process, receive a single infusion of the cell product, and then be closely observed in the clinic for about a month with regular check‑ups and simple tests to watch for any side effects or reactions.

The purpose of the study is to see how well these approaches shrink or control the tumors. Participants are randomly assigned to one of the treatment groups and receive a series of infusion visits over several weeks, with regular check‑ups to look at tumor size and overall health.

During the study, doctors will measure the objective response rate, which means the proportion of patients whose tumors get smaller or disappear, and will also watch for any side effects or changes in blood tests. The schedule includes clinic visits for the infusions, imaging scans to view the tumors, and laboratory tests to ensure safety.

The purpose of the trial is to determine whether the experimental drug can lower disease activity compared with a placebo. Adults will be randomly assigned to receive either the study drug or the placebo, and neither the participants nor the study staff will know which treatment is given. Injections will be given at regular intervals over about six months, with clinic visits to assess muscle strength, skin involvement, and any side effects. Researchers will track changes using simple scores that measure overall improvement and skin disease activity, and they will also monitor whether participants can reduce their steroid dose safely.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the trial is to see which of these treatments most effectively clears the bacteria from the lungs, a result known as microbiological eradication. Participants are randomly assigned to receive one of the three options for a short treatment period, then they return for regular check‑ups where sputum samples are collected and health questionnaires are completed to monitor safety, symptom changes, and overall well‑being.

Follow‑up continues for several months after the medication stops, allowing researchers to observe whether the infection stays cleared, how often lung flare‑ups occur, and any side effects that may appear. The information gathered will help determine the best approach to manage this bacterial infection in people with bronchiectasis.

The purpose of the study is to determine whether adding dasatinib can change the number and activity of important immune cells, specifically the white‑blood‑cell types called CD4, CD8 and CD56+. Participants will take either dasatinib or placebo for about a year, with regular clinic visits where blood samples are taken at several intervals (early after starting, then roughly every few months) to measure these cells, inflammation signals, and any side effects. Terms such as “viral reservoir” refer to the hidden virus that remains in cells despite treatment, and “inflammation markers” are blood signals that show how much inflammation is present.

Throughout the trial, doctors will closely watch for any adverse events, meaning any unwanted medical problems, and will perform routine laboratory tests to ensure safety. The study will track how the immune cells and inflammation markers change over time, providing information on whether dasatinib can offer additional benefit to people already on antiretroviral therapy.

The main purpose of the trial is to keep participants who are still benefiting from the drug under medical supervision while safety is monitored. After joining, participants will continue to receive opnurasib on a regular schedule for as long as it remains helpful and tolerable. Visits will include simple check‑ups to record any side effects, any changes in dosage, and overall health. The study does not involve any additional invasive procedures beyond the usual care for this condition.

The purpose of the study is to compare the effects of Odevixibat with a placebo in children with Biliary Atresia. Participants will receive either Odevixibat or a placebo once daily. The study will last for up to 104 weeks, during which time the health of the participants will be closely monitored. The main focus will be on the time it takes for participants to require a liver transplant or experience other serious health issues related to their liver condition.

Throughout the study, various health parameters will be assessed, including liver function tests and overall health status. The study aims to provide valuable information on whether Odevixibat can help improve the outcomes for children with Biliary Atresia who have had the Kasai procedure. Participants will be regularly checked for any side effects or changes in their health to ensure their safety during the trial.

The purpose of the trial is to identify a safe and effective dose of the new medication, to see how well it works against these cancers, and to understand how it interacts with other treatments. Early parts of the study increase the dose to find the highest amount patients can tolerate, followed by later parts that treat specific cancer types either alone or combined with the listed drugs. A small group of participants will also receive medicines that are processed by the enzymes CYP3A4 and CYP2C8 to check for possible drug‑interaction effects.

Participants will take the study tablet each day and receive the other medicines by intravenous infusion, meaning the drugs are given through a vein. Regular clinic visits will include physical checks, blood tests, and imaging scans that are evaluated using RECIST criteria, a system that measures how tumor size changes over time. The trial will continue for several months, with close monitoring for side effects, dose adjustments if needed, and assessments of tumor response.

The purpose of the study is to determine whether a three‑month course of MPD can improve thinking, attention, and overall quality of life compared with a control pill, which is a placebo. The trial is designed so that neither the participants nor the investigators know who receives the active drug or the control pill, ensuring an unbiased comparison.

Participants will take study tablets daily for three months and attend regular visits where simple brain‑activity recordings (explained as tests that measure the brain’s electrical signals) and mental‑function assessments (explained as tests that evaluate memory, problem‑solving, and attention) are performed, along with questionnaires about daily living and wellbeing.

Participants will receive one of the two medicines while they are under anesthesia for the surgery. After the operation, they will stay in the recovery area and be asked to rate their pain at several times during the first day. Pain will be measured with the Visual Analogue Scale, a simple line where patients mark how strong their pain feels, from “no pain” to “worst pain imaginable.” Researchers will also watch for common side effects such as nausea, itching, or breathing problems.

The follow‑up period lasts about 24 hours, during which the amount of additional pain medication needed and any unwanted reactions will be recorded. At the end of the study, the collected information will help decide if the new medication method can be used as an alternative to the current standard for managing pain after this surgery.

The purpose is to determine whether the combination is safe and works better than the usual chemotherapy plus rituximab. Safety is evaluated by recording any adverse events (unwanted medical problems) and any dose‑limiting toxicity (a side effect that prevents increasing the dose). Effectiveness is judged by the rate of complete response, meaning all detectable cancer disappears, and by PFS, the length of time a person lives without the disease getting worse.

Participants receive the study medicines in repeated cycles that last a few weeks, with regular clinic visits for blood tests, imaging scans, and overall health checks. After the treatment period, they are followed for several years to watch for any return of the cancer and to continue safety monitoring. All data are collected confidentially and in accordance with standard clinical‑trial procedures.

The purpose of the study is to evaluate how the treatment affects the objective response rate, which is the proportion of patients whose tumors shrink or disappear. After enrollment, participants are randomly assigned to one of the three treatment groups and receive the assigned therapy in repeated cycles over several months, with regular clinic visits for safety checks and blood draws. Tumor changes are measured using the standard imaging criteria known as RECIST, and any adverse events are closely monitored. Blood samples are also taken to assess the drug’s pharmacokinetics, meaning how the body absorbs and clears the medication.

Key outcomes include the percentage of patients achieving tumor shrinkage, the time until the disease shows progressive disease (when the cancer grows again), and the length of time patients remain alive, referred to as overall survival. Safety information and laboratory test results are collected throughout the study to understand the treatment’s risk profile.

The purpose of the study is to determine whether the combination of these two medicines is safe and works better than chemotherapy alone in slowing the disease. In the early part of the trial, different dose levels are tried to find the highest amount that can be given without causing unacceptable side effects, known as the “maximum tolerated dose.” Later, participants are randomly assigned to receive either the combination or the chemotherapy alone, and the time they live without the cancer getting worse, called “progression‑free survival,” is measured.

Participants would visit the clinic for regular intravenous infusions of the study drugs, followed by routine check‑ups that may include physical exams and imaging tests such as scans to see how the tumor is responding. The study lasts for several months, with visits scheduled to monitor health, record any side effects, and assess whether the cancer is stable, shrinking, or growing.

The purpose of the trial is to determine whether a shorter 5‑day course of the antibiotic is not worse than the standard 7‑day course in preventing a repeat infection, called a relapse, within about two weeks after treatment ends. Children between 2 and 17 years old will be assigned by chance to receive either the 5‑day or the 7‑day regimen, take the medicine at home, and then be followed for several weeks to see if fever goes away, if symptoms return, or if any complications develop. A relapse means the infection comes back after the prescribed antibiotics have been finished.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.